Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens

C.M. Fehres, H. Kalay, S.C.M. Bruijns, S.A.M. Musaafir, M. Ambrosini, L. van Bloois, S.J. van Vliet, G. Storm, J.J. Garcia Vallejo, Y. van Kooyk

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)67-76
JournalJournal of Controlled Release
Volume203
DOIs
Publication statusPublished - 2015

Cite this